Join Us at ISPOR!
Tuesday, May 7th from 4:30 – 6:30 PM EDT
White Oak Kitchen & Cocktails, 270 Peachtree St NW #100, Atlanta, GA 30303
Posters
Poster Session: 5
Poster Code: EE501
Date: Wednesday, May 8, 2024
Time: 9:00 AM – 11:30 AM EDT
Presenting Author: Richard Chapman, PhD (Innovation and Value Initiative) and Michelle Cheng, MHS (Innovation and Value Initiative)
Summary:
- Real-world evidence indicates that most patients diagnosed with major depressive disorder (MDD) typically cycle through different medications called selective serotonin reuptake inhibitors (SSRIs), but many remain untreated.
- We used IVI’s open-source MDD value model to examine clinical and economic outcomes, costs, and cost-effectiveness of a treatment pathway comprised of SSRI monotherapies through four lines of therapy vs. no treatment.
- Treating patients with SSRIs led to better clinical outcomes and was estimated to be cost-saving relative to no treatment.
Poster Session: 1
Poster Code: EE100
Date: Monday, May 6, 2024
Time: 10:30 AM – 1:30 PM EDT
Presenting Author: Tim Lai (Innovation and Value Initiative)
Summary:
- We searched the literature to identify approaches for incorporating equity considerations into economic evaluations.
- Distributional cost-effectiveness analysis (DCEA) was the most frequently discussed method, while the most frequently discussed challenge was lack of disaggregated data to perform equity-informed evaluations.
- We found that equity-related health economic literature has focused on more methods, with less attention to engagement processes or communication of results.
Poster Session: 5
Poster Code: PCR259
Date: Wednesday, May 8, 2024
Time: 9:00 AM – 11:30 AM EDT
Presenting Author: Rick Chapman, PhD (Innovation and Value Initiative)
Summary:
- A systematic, multi-domain approach to incorporating equity considerations into HTA is needed to ensure equitable and patient-centered decision-making.
- IVI engaged stakeholders through qualitative methods, including key informant interviews, expert roundtables, and its Methods Summit, to identify actionable changes to ensure accountability in HTA for identifying health disparities and addressing equity.
- This poster details accountability actions to ensure authentic patient engagement necessary for considering health disparities and accounting for equity as part of HTA.
- Changes in the people involved and processes used in HTA will be required by all stakeholders to ensure alignment with the goals of U.S. healthcare decision-makers.
Incorporating Stakeholder Perspectives into Open-Source Model Building for Major Depressive Disorder
Poster Code: PT1
Date: Monday, May 6, 2024
Time: 10:30 AM – 1:30 PM EDT
Presenting Author: Larragem Raines (Innovation and Value Initiative)
Summary:
- This work demonstrates the importance of utilizing multiple stakeholder perspectives when developing health economic models to ensure patient-centricity and equitable decision-making processes.
- A multi-stakeholder advisory group was established at the outset to provide ongoing guidance on the research, development, and dissemination of the model.
- The adoption of stakeholder perspectives into the model over the course of the design allowed for a more patient-centric focus that captures complexities pertinent to MDD patients, such as disparities, economic burden, and societal impacts, increasing the credibility and utility of the model.
Poster Code: PT7
Date: Monday, May 6, 2024
Time: 10:30 AM – 1:30 PM EDT
Presenting Author: Michelle Cheng, MHS (Innovation and Value Initiative)
Summary:
- Lack of consensus on assessing value and effectiveness of treatments for rare diseases adds uncertainty to the evidence informing healthcare decisions, potentially limiting patient access to innovative therapies.
- This research convened diverse stakeholders across multiple meetings to build a consensus on recommendations for enhancing patient-centered outcomes research for rare diseases.
- Seven key themes emerged regarding what matters most to patients, caregivers, and other stakeholders in developing approaches for comparative effectiveness and value assessment for rare diseases, including:
- Patient journey and time
- Caregiver journey
- Early and continuing engagement and communication
- Data and methods
- Economic impacts
- Scientific spillover
- Identifying common patient centered-outcomes.
Poster Session: 4
Poster Code: PCR199
Date: Tuesday, May 7, 2024
Time: 3:30 PM – 6:30 PM EDT
Presenting Author: Michelle Cheng, MHS (Innovation and Value Initiative)
Summary:
- This study aims to comprehend the attributes and outcomes that hold significance for patients grappling with rare diseases.
- A literature review was conducted to understand the documented research on rare diseases in the context of health technology assessment. It also aimed to explore outcomes related to select specific rare diseases.
- Through literature review and stakeholder engagement, this study identified patient-centered outcomes common to more than 5 out of 11 specific rare diseases, including physical functioning (motor, respiratory, speech), fatigue, social relationships, pain, mental deterioration, mental health, employment/work, economic impacts, and sleep.